15353-j-veluchamy

6 General discussion and Future Prospects | 153 Disease target Product stage AML Phase I/II Metastatic colon and non-small cell lung cancer Phase II AML and Solid tumors Phase I (AML) Solid tumors and haematological malignancies Phase I Ideally in combination with IgG 1 therapeutic mAbs in solid tumors (ex: cetuximab) and haematological malignancies (ex: rituximab) Preclinical NK-92 CARs are developed targeting tumor antigens in neuroblastoma, melanoma, breast cancer, multiple myeloma and leukemias Preclinical Solid tumors and lymphoma (NCT01212341) Phase I Solid tumors and haematological malignancies Preclinical Solid tumors and haematological malignancies Preclinical Solid tumors and haematological malignancies Preclinical Solid tumors and haematological malignancies Preclinical Osteosarcoma and hepatocellular carcinoma Preclinical Solid tumors and haematological malignancies Preclinical Cutaneous T cell lymphoma Phase III Chronic Lymphocytic leukemia Phase II Chronic lymphocytic leukemia Phase II Head and neck and KRAS mutant colorectal cancer Phase I / II Hodgkin’s lymphoma and lymphomas Phase II Head and neck and solid tumors Preclinical EGFR expressing solid tumors Preclinical Table 1: List of biotech NK cellular therapies and NK cell function enhancing compounds Comp ny NK cell product Product charact ristics Fortress Biotech Inc. CNDO-109 Tumor primed NK cells Mul mmune GmbH ENKASTIM-ev a synthetic peptide which mimics Hsp70 and activates NK cells ex vivo Glycostem Therapeutics oNKord ® NK cell derived from umbilical cord blood (UCB) progenitor cells NantKwest Inc. Activated NK-92 cells (aNK cell) IL-2 dep ndent tumor cell derived NK cell line High affinity NK cells (haNK) aNK c l s genetically modified to express CD16 for ADCC with therapeutic mAbs Targe - activated NK cells (taNK) aNK c l s genetically modified to express CARs Green Cross Lab Cell MG4101 Ex vivo xpanded NK cells derived from CD3 depleted unrelated donors Gamida Cell NAM-NK cells Nicotinam de based PBNK cell culture system Celgene Cellular Therapeutics NK cells NK cells derived from UCB and placenta. Fate Ther peutics Inc. iNK cells NK cells derived from induced pluripotent stem cells Sorrento Therap utics Inc CARs to enhance tumor homing of NK-92 cells NK-92 ells CAR targeting programming death ligand-1 and NK-92 CAR targeting receptor tyrosine kinase like orphan receptor to increase NK-92 tumor homing. Nk ta Therapeutics NKG2D CARs NKG2D CARs developed with NK-92 and PBNK to enhance the functions of NKG2D receptor in NK cells Ziopha m Oncology Inc. HLA gene editing Zinc finger nuclease technology to delete HLA-A sequences from allogeneic NK cells, allowing them to evade recipient T cell killing. Kyowa Hakko Kirin Mogamulizumab Fc optimized anti CCR4 CD20 mAb Genentec Obinutuzumab Fc optimized anti CD20 mAb Mentrik Bi tech, LLC Ocaratuzumab Fc optimized anti CD20 mAb Roche Glycart Imgatuzumab Fc optimized anti EGFR mAb Affimed N.V. AFM13 Bispecific antibody binding to CD16a on NK cells and CD30 on tumor cells AFM22 Bispecific antibody binding to CD16a on NK cells and epidermal growth factor receptor (EGFR) vIII on tumor cells AFM24 Bispecific antibody binding to CD16a on NK cells and wild type EGFR on tumor cells